Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of DN to kidney disease and, ultimately, kidney failure—a condition associated with severe morbidity / mortality and high costs to patients, payers, and healthcare systems. As a result, key opinion leaders indicate that efficacious therapies for DN are a major unmet need, and they weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and SGLT-2 inhibitor may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of DN, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing DN market over the next ten years.
Questions answered
Will the inclusion of cardiovascular endpoints in the clinical trials for select therapies be a competitive advantage once commercially available?
How do KOLs view the different mechanisms of action of the different therapies in early- and late-phase clinical development?
What are the greatest remaining unmet needs in DN? Which drugs in development will fulfill these unmet needs?
What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.